For the quarter ending 2026-03-31, SLNCF made $422K in revenue. -$14,957K in net income. Net profit margin of -3544.31%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Revenue | 422 | 82* | 159 | |
| Cost of sales | 11 | 23* | 64 | |
| Gross profit | 411 | 59* | 95 | |
| Research and development costs | 9,122 | 6,121* | 20,544 | |
| General and administrative expenses | 7,026 | 4,959* | 5,795 | |
| Restructuring charges | - | 1,324* | 0 | |
| Operating loss | -15,737 | -12,345* | -26,244 | |
| Foreign currency gain/(loss), net | -482 | -14,269* | 1,934 | |
| Other income, net | 571 | 1,170* | 770 | |
| Benefit from r&d credit | 691 | -286* | 2,583 | |
| Loss before income tax expense | -14,957 | -25,730* | -20,957 | |
| Income tax expense | 0 | 8* | 1 | |
| Net loss | -14,957 | -25,738 | -20,958 | |
| Basic EPS | -0.11 | -0.182 | -0.15 | |
| Diluted EPS | -0.11 | -0.182 | -0.15 | |
| Basic Average Shares | 141,702,578 | 141,687,556 | 141,701,848 | |
| Diluted Average Shares | 141,702,578 | 141,687,556 | 141,701,848 | |
Silence Therapeutics plc (SLNCF)
Silence Therapeutics plc (SLNCF)